Acquisition History / Guardant Health / MetaSight
Guardant Health Acquires MetaSight
Announced February 20, 2026 — $150M
What happened
MetaSight is an Israeli liquid biopsy cancer-detection startup. Guardant Health acquired it for up to US$150M and will make it its first R&D centre outside the US.
- Acquirer
- Guardant Health
- Target
- MetaSight
- Announced
- February 20, 2026
- Price
- $150M
- Industry
- Liquid biopsy cancer detection
- Buyer type
- Strategic acquirer
- Status
- Announced, not yet closed
By the numbers
Frequently Asked Questions About This Acquisition
When did Guardant Health acquire MetaSight?
Guardant Health acquired MetaSight on February 20, 2026. This was Guardant Health's 1st publicly tracked acquisition out of 1 we have on record.
How much did Guardant Health pay for MetaSight?
Guardant Health paid $150M for MetaSight.
What does MetaSight do?
MetaSight is an Israeli liquid biopsy cancer-detection startup. Guardant Health acquired it for up to US$150M and will make it its first R&D centre outside the US.
What other Liquid biopsy cancer detection companies has Guardant Health acquired?
MetaSight is Guardant Health's only publicly tracked acquisition in Liquid biopsy cancer detection so far.